Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence

References

• Bernstein JA, Lang DM, Khan DA. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270–1277.
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M, Metz M, et al. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J German Soc Dermatol. 2013;11(10):971–978.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–887.
   PubMed Web of Science ®Google Scholar
• Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria: a GA2LEN task force report. Allergy. 2011;66:317–330.
   PubMed Web of Science ®Google Scholar
• Broder MS, Raimundo K, Antonova E, et al. Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria. Am J Clin Dermatol. 2015;16:313–321.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Balke M, Worm M, et al. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869–873.
   PubMed Web of Science ®Google Scholar
• Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;00:1–11.
   Google Scholar
• Soni A, Mitchell E. Expenditures for commonly treated conditions among adults age 18 and older in the U.S. civilian noninstitutionalized population, 2013. Statistical Brief #487. Rockville (MD): Agency for Healthcare Research and Quality; May 2016. [cited 2017 Nov 3]. Available from: http://www.meps.ahrq.gov/mepsweb/data_files/publications/st487/stat487.pdf
   Google Scholar
• Tharp MD. Chronic urticaria: pathophysiology and treatment approaches. J Allergy Clin Immunol. 1996;98(6):S325–S330.
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A, Marzano AV, et al. Pathomechanisms of chronic spontaneous urticaria: what is known and up to date. Curr Derm Rep. 2014;3:191–196.
   Google Scholar
• Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337–342.
   PubMed Web of Science ®Google Scholar
• Fine LM, Bernstein JA. Guideline of chronic urticaria beyond. Allergy Asthma Immunol Res. 2016;8(5):396–403.
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Chronic spontaneous urticaria: pathogenesis and treatment considerations. Allergy Asthma Immunol Res. 2017;9(6):477–482.
   PubMed Web of Science ®Google Scholar
• Greiwe J, Bernstein JA. Therapy of antihistamine-resistant chronic spontaneous urticaria. Expert Rev Clin Immunol. 2017;13(4):311–318.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. The EAACI/GA(2) LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64:1427–1443.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Greaves MW, Juhlin L, et al. Management of urticaria: a consensus report. J Investig Dermatol Symp Proc. 2001;6:128–131.
   PubMedGoogle Scholar
• European Medicines Agency. Xolair: summary of product characteristics. [cited 2016 Oct 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf.
   Google Scholar
• Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007;99(2):190–193.
   PubMed Web of Science ®Google Scholar
• Dreyfus DH. Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema. Ann Allergy Asthma Immunol. 2008;100(6):624–625.
   PubMed Web of Science ®Google Scholar
• Godse KV. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol. 2008;74(2):157.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122(3):569–573.
   PubMed Web of Science ®Google Scholar
• Máspero JF, Parisi CA, De Gennaro M, et al. Chronic autoimmune urticaria: treatment with omalizumab. Archivos Argentinos De Pediatria. 2009;107(5):452–456.
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109.
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H 1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75.
   PubMed Web of Science ®Google Scholar
• Abraham I, Alhossan A, Lee CS, et al. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71:593–610.
   PubMed Web of Science ®Google Scholar
• Ivyanskiy I, Sand C, Thomsen SF. Omalizumab for chronic urticaria: a case series and overview of the literature. Case Rep Dermatol. 2012;4(1):19–26.
   PubMedGoogle Scholar
• Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12(4):406–411.
   PubMed Web of Science ®Google Scholar
• Francés L, Leiva-Salinas M, Silvestre JF. Omalizumab in the treatment of chronic urticaria. Actas Dermo-Sifiliográficas (English Edition). 2014;105(1):45–52.
   Google Scholar
• Lang DM. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema. Ann Allergy Asthma Immunol. 2014;112(4):276–279.
   PubMed Web of Science ®Google Scholar
• Giménez-Arnau AM, Toubi E, Marsland AM, et al. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2016;30(S5):25–32.
   PubMedGoogle Scholar
• Vestergaard C, Toubi E, Maurer M, et al. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Eur J Dermatol. 2017;27(1):10–19.
   PubMed Web of Science ®Google Scholar
• Giménez-Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017;17(3):375–385.
   PubMed Web of Science ®Google Scholar
• Tonacci A, Billeci L, Pioggia G, et al. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature. Pharmacotherapy. 2017;37(4):464–480.
   PubMed Web of Science ®Google Scholar
• Chia JC, Mydlarski PR. Dermatologic uses of omalizumab. J Dermatolog Treat. 2017;28(4):332–337.
   PubMed Web of Science ®Google Scholar
• Ghazanfar MN, Thomsen SF. Omalizumab for chronic urticaria: aftermarket reports of efficacy and side effects. Curr Dermatol Rep. 2017;6(2):48–54.
   Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1–9.
   PubMed Web of Science ®Google Scholar
• Młynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63:777–780.
   PubMed Web of Science ®Google Scholar
• Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133:1365–1372.
   PubMed Web of Science ®Google Scholar
• Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy. 2005;60:1073–1078.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine use. Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• Iemoli E, Piconi S, Fusi A, et al. Immunological effects of omalizumab in chronic urticaria: a case report. J Investig Allergol Clin Immunol. 2010;20(3):252–254.
   PubMed Web of Science ®Google Scholar
• Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol. 2010;90(4):443–444.
   PubMed Web of Science ®Google Scholar
• Wieczorek D, Kapp A, Wedi B. Omalizumab treatment of different urticaria subtypes. Allergo J. 2011;20(5):244–248.
   Google Scholar
• Armengot-Carbo M, Velasco-Pastor M, Rodrigo-Nicolas B, et al. Omalizumab in chronic urticaria: a retrospective series of 15 cases. Dermatol Ther. 2013;26(3):257–259.
   PubMed Web of Science ®Google Scholar
• Song CH, Stern S, Giruparajah M, et al. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2013;110(2):113–117.
   PubMed Web of Science ®Google Scholar
• Kai AC, Flohr C, Grattan CE. Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis. Clin Exp Dermatol. 2014;39(5):651–652.
   PubMed Web of Science ®Google Scholar
• Romano C, Sellitto A, De Fanis U, et al. Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. Clin Drug Investig. 2015;35(3):159–168.
   PubMed Web of Science ®Google Scholar
• Tontini C, Marinangeli L, Cognigni M, et al. Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation? Ann Allergy Asthma Immunol. 2015;115(2):147–148.
   PubMed Web of Science ®Google Scholar
• Clark JJ, Secrest AM, Hull CM, et al. The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: retrospective chart review. J Am Acad Dermatol. 2016;74(6):1274–1276.
   PubMed Web of Science ®Google Scholar
• Denman S, Ford K, Toolan J, et al. Home self-administration of omalizumab for chronic spontaneous urticaria. Br J Dermatol. 2016;175(6):1405–1407.
   PubMed Web of Science ®Google Scholar
• Giménez-Arnau A, Velasco M, Hita JC, et al. Omalizumab: what benefits should we expect? Eur J Dermatol. 2016;26(4):340–344.
   PubMed Web of Science ®Google Scholar
• Gómez-Vera J, Gutiérrez-Ávila SA, Acosta-Gutiérrez DN, et al. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults. Ann Allergy Asthma Immunol. 2016;117(2):204–206.
   PubMed Web of Science ®Google Scholar
• Gönül M, Özenergün Bittacı A, Ergin C. Omalizumab-induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2016;30(11):e135–e136.
   PubMed Web of Science ®Google Scholar
• Konstantinou GN, Chioti AG, Daniilidis M. Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect? Eur Ann Allergy Clin Immunol. 2016;48(5):205–207.
   PubMed Web of Science ®Google Scholar
• Moreira AC, Lopes MR, Silva SE. Use of omalizumab in the treatment of chronic urticaria. Eur Ann Allergy Clin Immunol. 2016;48(6):242–246.
   PubMed Web of Science ®Google Scholar
• Subramaniyan R, Chopra A. Treatment of chronic spontaneous urticaria with a single dose of omalizumab: a study of four cases. Indian J Dermatol. 2016;61(4):467.
   PubMed Web of Science ®Google Scholar
• Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;140(6):1749–1751.
   PubMed Web of Science ®Google Scholar
• Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139(3):1059–1061.
   PubMed Web of Science ®Google Scholar
• Kocatürk E, Can PK, Akbas PE, et al. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study. J Dermatol Sci. 2017;87(1):60–69.
   PubMed Web of Science ®Google Scholar
• Kulthanan K, Tuchinda P, Chularojanamontri L, et al. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population. J Dermatol Treat. 2017;28(2):160–165.
   PubMed Web of Science ®Google Scholar
• Larrea-Baca I, Gurpegui-Resano M. Improvement in the quality of life of patients with chronic spontaneous urticaria treated with omalizumab in real life. Enferm Clin. 2017;27(6):361–368.
   PubMed Web of Science ®Google Scholar
• Al-Ahmad M. Omalizumab therapy in three patients with chronic autoimmune urticaria. Ann Saudi Med. 2010;30(6):478.
   PubMed Web of Science ®Google Scholar
• Korkmaz H, Eigelshoven S, Homey B. Omalizumab for therapy-resistant chronic urticaria with angioedema. Hautarzt. 2010;61(10):828–831.
   PubMed Web of Science ®Google Scholar
• Ferrer M, Gamboa P, Sanz ML, et al. Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol. 2011;127(5):1300–1302.
   PubMed Web of Science ®Google Scholar
• Košnik M, Kopač P, Eržen R, et al. Omalizumab in chronic urticaria: our experience and literature review. Acta Dermatovenerol Alp Panonnica Adriat. 2014;23(3):57–61.
   PubMedGoogle Scholar
• Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria. Ann Allergy Asthma Immunol. 2015;115(2):126–129.
   PubMed Web of Science ®Google Scholar
• Irani C, Nahas O. Real-life experience of clinical efficacy of omalizumab use in the Middle East: should we also be concerned about parasites? Clin Antiinflamm Antiallergy Drugs. 2015;2(1):43–46.
   Google Scholar
• Seth S, Khan DA. The comparative safety of multiple alternative agents in refractory chronic urticaria patients. J Allergy Clin Immunol Pract. 2017;5(1):165–170.
   PubMed Web of Science ®Google Scholar
• Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol. 2006;96(4):624–627.
   PubMed Web of Science ®Google Scholar
• Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol. 2010;126(3):665–666.
   PubMed Web of Science ®Google Scholar
• Godse KV. Omalizumab in treatment-resistant chronic spontaneous urticaria. Indian J Dermatol. 2011;56(4):444.
   PubMedGoogle Scholar
• Groffik A, Mitzel-Kaoukhov H, Magerl M, et al. Omalizumab–an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy. 2011;66(2):303–305.
   PubMed Web of Science ®Google Scholar
• Saavedra MC, Sur S. Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy. 2011;9(1):2.
   PubMedGoogle Scholar
• Sánchez-Machín I, Iglesias-Souto J, Franco A, et al. T cell activity in successful treatment of chronic urticaria with omalizumab. Clin Mol Allergy. 2011;9(1):11.
   PubMedGoogle Scholar
• Nam YH, Kim JH, Jin HJ, et al. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res. 2012;4(6):357–361.
   PubMed Web of Science ®Google Scholar
• Díez LS, Tamayo LM, Cardona R. Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases. Biomedica. 2013;33(4):503–512.
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther. 2013;13(9):1225–1228.
   PubMed Web of Science ®Google Scholar
• Lefévre AC, Deleuran M, Vestergaard C. A long term case series study of the effect of omalizumab on chronic spontaneous urticaria. Ann Dermatol. 2013;25(2):242–245.
   PubMed Web of Science ®Google Scholar
• Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria. Allergy Asthma Proc. 2013;34(5):446–452.
   PubMed Web of Science ®Google Scholar
• Fiorino I, Loconte F, Rucco AS, et al. Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases. Postȩpy Dermatol Alergol. 2014;31(5):332.
   PubMed Web of Science ®Google Scholar
• Metz M, Ohanyan T, Church MK, et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73(1):57–62.
   PubMed Web of Science ®Google Scholar
• Rottem M, Segal R, Kivity S, et al. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience. Isr Med Assoc J. 2014;16(8):487–490.
   PubMed Web of Science ®Google Scholar
• Uysal P, Eller E, Mortz CG, et al. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. J Allergy Clin Immunol. 2014;133(3):914–915.
   PubMed Web of Science ®Google Scholar
• Van Den Elzen MT, Rockmann H, Sanders CJG, et al. Treatment of chronic urticaria with omalizumab. Ned Tijdschr Dermatol Venereol. 2014;24(5):253–256.
   Google Scholar
• Vieira Dos Santos R, Locks Bidese B, Rabello de Souza J, et al. Effects of omalizumab in a patient with three types of chronic urticaria. Br J Dermatol. 2014;170(2):469–471.
   PubMed Web of Science ®Google Scholar
• Ghazanfar MN, Thomsen SF. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies. Case Rep Med. 2015;2015:368053.
   PubMedGoogle Scholar
• Klossowski N, Braun SA, Von Gruben V, et al. Acquired angioedema with C1-INH deficiency and accompanying chronic spontaneous urticaria in a patient with chronic lymphatic B cell leukemia. Hautarzt. 2015;66(10):723–725.
   PubMed Web of Science ®Google Scholar
• Leiva-Salinas M, Francés L, Marin-Cabanas I, et al. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C. J Eur Acad Dermatol Venereol. 2015;29(5):1027–1028.
   PubMed Web of Science ®Google Scholar
• Lundberg C, Martinez B, Banks TA. Expanding the spectrum: chronic urticaria and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Ann Allergy Asthma Immunol. 2015;114(4):353–354.
   PubMed Web of Science ®Google Scholar
• Netchiporouk E, Nguyen CH, Thuraisingham T, et al. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatr Allergy Immunol. 2015;26(6):585–588.
   PubMed Web of Science ®Google Scholar
• Savic S, Marsland A, McKay D, et al. Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. Allergy Asthma Clin Immunol. 2015;11(21):1–11.
   PubMedGoogle Scholar
• Silva PM, Costa AC, Mendes A, et al. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol (Madr). 2015;43(2):168–173.
   PubMed Web of Science ®Google Scholar
• Sussman G, Gonçalo M, Sánchez-Borges M. Treatment dilemmas in chronic urticaria. J Eur Acad Dermatol Venereol. 2015;29(S3):33–37.
   PubMedGoogle Scholar
• Wieder S, Maurer M, Lebwohl M. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues. Am J Clin Dermatol. 2015;16(1):19–26.
   PubMed Web of Science ®Google Scholar
• Bongiorno MR, Crimi N, Corrao S, et al. Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice. Ann Allergy Asthma Immunol. 2016;117(6):703–707.
   PubMed Web of Science ®Google Scholar
• Cuervo-Pardo L, Barcena-Blanch M, Radojicic C. Omalizumab use during pregnancy for CIU: a tertiary care experience. Eur Ann Allergy Clin Immunol. 2016;48(4):145–146.
   PubMed Web of Science ®Google Scholar
• Dawicka J, Wilkowska A, Grubska-Suchanek E, et al. Omalizumab in the treatment of chronic spontaneous urticaria–literature review and own experience. Przegl Dermatol. 2016;103(1):64–70.
   Web of Science ®Google Scholar
• Ensina LF, Valle SO, Juliani AP, et al. Omalizumab in chronic spontaneous urticaria: a Brazilian real-life experience. Int Arch Allergy Immunol. 2016;169(2):121–124.
   PubMed Web of Science ®Google Scholar
• Ertaş R, Özyurt K, Yıldız S, et al. Adverse reaction to omalizumab in patients with chronic urticaria: flare up or ineffectiveness? Iran J Allergy Asthma Immunol. 2016;15(1):82–86.
   PubMed Web of Science ®Google Scholar
• Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatology. 2016;175(2):404–406.
   PubMed Web of Science ®Google Scholar
• Gozdzik-Spychalska J, Rzymkowska M, Batura-Gabryel H. Chronic urticaria in a patient with severe atopic asthma-double benefit from treatment with omalizumab. Pol J Allergol. 2016;3:S28–S30.
   Google Scholar
• Kasperska-Zajac A, Jarząb J, Żerdzińska A, et al. Effective treatment of different phenotypes of chronic urticaria with omalizumab: case reports and review of literature. Int J Immunopathol Pharmacol. 2016;29(2):320–328.
   PubMed Web of Science ®Google Scholar
• Olszowiec-Chlebna M, Sztafińska A, Stelmach I. Teenager suffered from idiopathic anaphylaxis and chronic spontaneous urticaria successfully treated with omalizumab: a case report. Pediatr Allergy Immunol Pulmonol. 2016;29(1):53–55.
   Web of Science ®Google Scholar
• Osmenda G, Jasiewicz-Honkisz B. Severe asthma-biological treatment with omalizumab-case report. Pol J Allergol. 2016;3:S26–S27.
   Google Scholar
• Palacios T, Stillman L, Borish L, et al. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2016;4(3):529.
   PubMed Web of Science ®Google Scholar
• Shahzad H. A case of refractory chronic spontaneous urticaria treated with omalizumab. J Pakistan Assoc Dermatol. 2016;26(3):276–278.
   Google Scholar
• Wilches P, Wilches P, Calderon JC, et al. Omalizumab for chronic urticaria in Latin America. World Allergy Organ J. 2016;9(1):36.
   PubMedGoogle Scholar
• Asero R, Marzano AV, Ferrucci S, et al. D-dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol. 2017;172(1):40–44.
   PubMed Web of Science ®Google Scholar
• Chicharro P, Rodríguez-Jiménez P, De Argila D. Efficacy and safety of omalizumab in a patient with chronic spontaneous urticaria and active hepatitis B virus infection. Actas Dermosifiliogr (English Edition). 2017;108(4):383–384.
   PubMedGoogle Scholar
• Deza G, Bertolín-Colilla M, Pujol RM, et al. Basophil FcεRI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017;97(6):698–704.
   PubMed Web of Science ®Google Scholar
• González-Medina M, Curto-Barredo L, Labrador-Horrillo M, et al. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases. J Eur Acad Dermatol Venereol. 2017;31(5):e245–e246.
   PubMed Web of Science ®Google Scholar
• Iemoli E, Niero F, Borgonovo L, et al. Successful omalizumab treatment in HIV positive patient with chronic spontaneous urticaria: a case report. Eur Ann Allergy Clin Immunol. 2017;49(2):88.
   PubMed Web of Science ®Google Scholar
• Marín-Cabañas I, Berbegal-De Gracia L, De León-Marrero F, et al. Management of chronic spontaneous urticaria in routine clinical practice following the EAACI/GA (2) LEN/EDF/WAO guidelines. Actas Dermosifiliogr (English Edition). 2017;108(4):346–353.
   PubMedGoogle Scholar
• Pinto Gouveia M, Gameiro A, Pinho A, et al. Long-term management of chronic spontaneous urticaria with omalizumab. Clin Exp Dermatol. 2017;42(7):735–742.
   PubMed Web of Science ®Google Scholar
• Porcaro F, Di Marco A, Cutrera R. Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. Pediatr Pulmonol. 2017;52(5):e26–e28.
   PubMed Web of Science ®Google Scholar
• Türk M, Yılmaz I, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: real life experience with twenty-five patients. Allergol Int. 2018;67(1):85–89. First identified in search as e-pub ahead of print : 2017 May 26. DOI:10.1016/j.alit.2017.05.003
   PubMed Web of Science ®Google Scholar
• Büyüköztürk S, Gelincik A, Demirtürk M, et al. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol. 2012;39(5):439–442.
   PubMed Web of Science ®Google Scholar
• Metz M, Ohanyan T, Church MK, et al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150(3):288–290.
   PubMed Web of Science ®Google Scholar
• Sussman G, Hébert J, Barron C, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol. 2014;112(2):170–174.
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, et al. “Real-life” effectiveness studies of omalizumab in patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5:1362–1370.
   PubMed Web of Science ®Google Scholar
• Asero R. ACE inhibitors may interfere with omalizumab in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017;31(8):e358–e359.
   PubMed Web of Science ®Google Scholar
• Wang L, Ke X, Kavati A, et al. Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria. Curr Med Res Opin. 2018;34(1):35–39.
   PubMed Web of Science ®Google Scholar
• Maurer M, Raap U, Staubach P, et al. Hospital compared to private practice dermatologist treatment of chronic spontaneous urticaria: baseline characteristics and treatment patterns from the German AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) study. Allergy. 2016;71(Suppl. 102):184.
   Google Scholar
• Thomsen SF, Pritzier EC, Anderson CD, et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol. 2017;31(6):1048–1055.
   PubMed Web of Science ®Google Scholar
• Mosteller F. Improving research methodology. In: Sechrest L, Perrin E, Bunker J, editors. Research Methodology: Strengthening Causal Interpretations of Nonexperimental Data (Conference Proceedings, Tucson, AZ, 8–10 April 1987; PHS Report 90-3454). Department of Health and Human Services, Public Health Services, Agency for Health Care Policy and Research; 1990. Available on CD-ROM from the National Technical Information Service. Springfield, VA; 1987:221–230. PB90-101387.
   Google Scholar